Equities research analysts predict that Agenus Inc (NASDAQ:AGEN) will announce sales of $9.03 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Agenus’ earnings, with estimates ranging from $8.75 million to $9.30 million. The business is scheduled to issue its next quarterly earnings results on Monday, May 6th.
On average, analysts expect that Agenus will report full-year sales of $25.04 million for the current financial year, with estimates ranging from $12.77 million to $37.30 million. For the next year, analysts forecast that the business will report sales of $9.32 million, with estimates ranging from $2.64 million to $16.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Agenus.
Agenus (NASDAQ:AGEN) last issued its quarterly earnings data on Thursday, March 14th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.12). The company had revenue of $5.36 million for the quarter, compared to analysts’ expectations of $6.67 million.
NASDAQ AGEN traded down $0.03 during trading on Friday, reaching $2.57. 4,016 shares of the stock traded hands, compared to its average volume of 1,053,164. The stock has a market cap of $344.92 million, a P/E ratio of -1.78 and a beta of 2.07. Agenus has a fifty-two week low of $1.54 and a fifty-two week high of $4.80.
Several institutional investors have recently added to or reduced their stakes in the company. Ingalls & Snyder LLC acquired a new position in shares of Agenus in the first quarter valued at approximately $594,000. Geode Capital Management LLC boosted its holdings in shares of Agenus by 34.1% in the fourth quarter. Geode Capital Management LLC now owns 1,062,200 shares of the biotechnology company’s stock valued at $2,528,000 after buying an additional 269,890 shares during the period. Amalgamated Bank acquired a new position in shares of Agenus in the fourth quarter valued at approximately $30,000. Millennium Management LLC boosted its holdings in shares of Agenus by 58.8% in the fourth quarter. Millennium Management LLC now owns 1,021,387 shares of the biotechnology company’s stock valued at $2,431,000 after buying an additional 378,345 shares during the period. Finally, RTW Investments LP boosted its holdings in shares of Agenus by 3.2% in the fourth quarter. RTW Investments LP now owns 10,135,119 shares of the biotechnology company’s stock valued at $24,122,000 after buying an additional 310,540 shares during the period. Institutional investors own 28.39% of the company’s stock.
Agenus Company Profile
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.
Featured Story: The components of the Stochastic Momentum Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.